President Joe Biden’s “Inflation Reduction Act” Drug Savings Fall Short of the Hype

President Joe Biden’s so-called Inflation Reduction Act (IRA) was sold as a major deficit-reduction and drug-savings package. The numbers now point in the opposite direction.

A new analysis from the Paragon Health Institute finds that Medicare Part D spending has surged since the law’s enactment. Instead of producing immediate savings, federal drug outlays have increased.

What Was Promised

At the time of passage, supporters argued the IRA would significantly reduce federal deficits. The Congressional Budget Office (CBO) originally estimated that the law would reduce federal spending by roughly $160 billion over a decade, largely due to projected savings from its drug pricing provisions.

That projected savings figure became a central talking point in the political debate.

What the Updated Data Show

According to Paragon, Medicare Part D spending has climbed rather than declined. The structure of the law shifted more financial responsibility onto the federal government, especially in the catastrophic phase of the benefit.

Shifting more liability to taxpayers does not eliminate costs. It raises federal spending even if some costs are redistributed within the program.

The concerns are not limited to one outside analysis. Writing at the American Enterprise Institute, Jim Capretta notes that updated CBO estimates show a substantial erosion of the IRA’s projected deficit reduction. What was once estimated to produce $160 billion in savings now appears far less certain, with federal drug spending running higher than originally forecast.

In short, the fiscal picture looks worse than advertised.

Why This Matters

Washington often promises savings through centralized price-setting. But healthcare markets are complex. When government increases its share of liability in one part of the system, total federal costs can rise even if individual drug prices are constrained.

If overall Part D spending is increasing rather than decreasing, then the core promise of the law is in doubt.

There is also the long-term question of innovation. Pharmaceutical development depends on predictable returns and investment incentives. Government price controls introduce uncertainty and can dampen research over time.

CFE Takeaway

President Biden’s “Inflation Reduction Act” was marketed as a deficit-reduction and drug-savings breakthrough. Early data suggest Medicare drug spending is higher, not lower, and projected deficit reduction has eroded.

If the goal is affordability and fiscal discipline, policymakers should focus on competition, transparency, and structural reform. Expanding federal liability while claiming savings is not a durable solution.